Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 4
2016 1
2017 7
2018 8
2019 9
2020 10
2021 7
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, Haj Mohammad N, Ruurda JP, van Hillegersberg R, Mook S, Nieuwdorp M, de Gruijl TD, Soeratram TTD, Ylstra B, van Grieken NCT, Bijlsma MF, Hulshof MCCM, van Laarhoven HWM. van den Ende T, et al. Among authors: van laarhoven hwm, bijlsma mf. Clin Cancer Res. 2021 Jun 15;27(12):3351-3359. doi: 10.1158/1078-0432.CCR-20-4443. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504550 Clinical Trial.
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial.
van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, van Dieren S, Dijkgraaf MG, Gerhards MF, de Hingh IH, Karsten TM, Lips DJ, Luyer MD, Busch OR, Festen S, Besselink MG; Dutch Pancreatic Cancer Group. van Hilst J, et al. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):199-207. doi: 10.1016/S2468-1253(19)30004-4. Epub 2019 Jan 24. Lancet Gastroenterol Hepatol. 2019. PMID: 30685489 Clinical Trial.
Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types.
van den Ende T, van den Boorn HG, Hoonhout NM, van Etten-Jamaludin FS, Meijer SL, Derks S, de Gruijl TD, Bijlsma MF, van Oijen MGH, van Laarhoven HWM. van den Ende T, et al. Among authors: van laarhoven hwm, bijlsma mf. Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188386. doi: 10.1016/j.bbcan.2020.188386. Epub 2020 Jun 12. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32540465 Free article.
Readily available biomarkers predict poor survival in metastatic pancreatic cancer.
Strijker M, van Veldhuisen E, van der Geest LG, Busch OR, Bijlsma MF, Haj Mohammad N, Homs MY, van Hooft JE, Verheij J, de Vos-Geelen J, Wilmink JW, Steyerberg WEW, Besselink MG, van Laarhoven HW; Dutch Pancreatic Cancer Group. Strijker M, et al. Among authors: van laarhoven hw, bijlsma mf. Biomarkers. 2021 Jun;26(4):325-334. doi: 10.1080/1354750X.2021.1893814. Epub 2021 Mar 21. Biomarkers. 2021. PMID: 33663300
The dynamics of HER2 status in esophageal adenocarcinoma.
Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM. Creemers A, et al. Among authors: van laarhoven hwm, bijlsma mf. Oncotarget. 2018 Jun 1;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 1. Oncotarget. 2018. PMID: 29928485 Free PMC article.
High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1.
Steins A, van Mackelenbergh MG, van der Zalm AP, Klaassen R, Serrels B, Goris SG, Kocher HM, Waasdorp C, de Jong JH, Tekin C, Besselink MG, Busch OR, van de Vijver MJ, Verheij J, Dijk F, van Tienhoven G, Wilmink JW, Medema JP, van Laarhoven HW, Bijlsma MF. Steins A, et al. Among authors: van laarhoven hw, bijlsma mf. EMBO Rep. 2020 May 6;21(5):e48780. doi: 10.15252/embr.201948780. Epub 2020 Mar 16. EMBO Rep. 2020. PMID: 32173982 Free PMC article.
Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.
Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, Verheij J, Meijer SL, Dijk F, Bijlsma MF, van Oijen MGH, van Laarhoven HWM. Creemers A, et al. Among authors: van laarhoven hwm, bijlsma mf. Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):394-403. doi: 10.1016/j.bbcan.2017.08.002. Epub 2017 Aug 8. Biochim Biophys Acta Rev Cancer. 2017. PMID: 28801248 Review.
Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets.
Le Large TY, Mantini G, Meijer LL, Pham TV, Funel N, van Grieken NC, Kok B, Knol J, van Laarhoven HW, Piersma SR, Jimenez CR, Kazemier G, Giovannetti E, Bijlsma MF. Le Large TY, et al. Among authors: van laarhoven hw, bijlsma mf. JCI Insight. 2020 Aug 6;5(15):e138290. doi: 10.1172/jci.insight.138290. JCI Insight. 2020. PMID: 32634123 Free PMC article.
47 results